Oculis Holding AG Ordinary shares (OCS) - Total Assets
Based on the latest financial reports, Oculis Holding AG Ordinary shares (OCS) holds total assets worth $236.23 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Oculis Holding AG Ordinary shares cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Oculis Holding AG Ordinary shares - Total Assets Trend (2020–2025)
This chart illustrates how Oculis Holding AG Ordinary shares's total assets have evolved over time, based on quarterly financial data. See net assets of Oculis Holding AG Ordinary shares for net asset value and shareholders' equity analysis.
Oculis Holding AG Ordinary shares - Asset Composition Analysis
Current Asset Composition (December 2025)
Oculis Holding AG Ordinary shares's total assets of $236.23 Million consist of 92.8% current assets and 7.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.5% |
| Accounts Receivable | $994.13K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $13.31 Million | 5.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Oculis Holding AG Ordinary shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Oculis Holding AG Ordinary shares (OCS) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oculis Holding AG Ordinary shares's current assets represent 92.8% of total assets in 2025, an increase from 37.6% in 2020.
- Cash Position: Cash and equivalents constituted 34.5% of total assets in 2025, up from 30.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 53.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 5.6% of total assets.
Oculis Holding AG Ordinary shares Competitors by Total Assets
Key competitors of Oculis Holding AG Ordinary shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Oculis Holding AG Ordinary shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.96 | 2.37 | 11.81 |
| Quick Ratio | 5.96 | 2.37 | 12.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $182.35 Million | $60.66 Million | $43.92 Million |
Oculis Holding AG Ordinary shares - Advanced Valuation Insights
This section examines the relationship between Oculis Holding AG Ordinary shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.54 |
| Latest Market Cap to Assets Ratio | 2.78 |
| Asset Growth Rate (YoY) | 96.3% |
| Total Assets | $236.23 Million |
| Market Capitalization | $655.80 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Oculis Holding AG Ordinary shares's assets at a significant premium (2.78x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Oculis Holding AG Ordinary shares's assets grew by 96.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oculis Holding AG Ordinary shares (2020–2025)
The table below shows the annual total assets of Oculis Holding AG Ordinary shares from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $236.23 Million | +96.28% |
| 2024-12-31 | $120.35 Million | +5.25% |
| 2023-12-31 | $114.35 Million | +208.56% |
| 2022-12-31 | $37.06 Million | -36.15% |
| 2021-12-31 | $58.04 Million | +254.29% |
| 2020-12-31 | $16.38 Million | -- |
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candida… Read more